Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page footer revision was updated from v3.6.5 to v3.6.6, indicating a minor update to the page rendering.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe record history now lists a new revision entry Revision: v3.6.5, replacing Revision: v3.6.4, indicating an update to the page's version metadata.SummaryDifference0.1%

- Check49 days agoChange DetectedThe revision label on the history page was updated to v3.6.4, indicating a new version of the interface used for the page.SummaryDifference0.1%

- Check71 days agoChange DetectedThe history now shows the addition of Revision: v3.6.3 and the removal of Revision: v3.6.2, signaling a new site release label. This reflects a minor update to the page's release version in the record history without changes to the underlying study information.SummaryDifference0.1%

- Check78 days agoChange DetectedThe record history now includes a new site revision entry (v3.6.2). The previous revision (v3.6.0) has been removed, indicating a backend version update rather than changes to trial data.SummaryDifference0.1%

- Check92 days agoChange DetectedThe history now shows that the study is no longer recruiting participants, indicating enrollment closure. It also adds a new revision tag (v3.6.0) and removes the previous revision tag (v3.5.5), reflecting an updated version in the study record.SummaryDifference0.2%

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.